BREAST: CB-2-23 | ASCENT-05
Trial ID
NCT05633654
Trial Sponsor
Gilead Sciences
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)